Introduction to Estazolam’s Therapeutic and Market Significance​ Estazolam, a benzodiazepine derivative approved for treating insomnia and anxiety disorders, occupies a strategic position in the global pharmaceutical market. With over 700 million people worldwide affected by insomnia and approximately 300 million suffering from anxiety-related conditions, the demand for established treatments like Estazolam remains robust despite the emergence of newer alternatives . First approved by the FDA in 1990, Estazolam has transitioned to a predominantly generic market since its patent expiration in 2007, creating a competitive landscape with diverse procurement channels and pricing structures . This analysis examines the global buyer ecosystem for Estazolam, identifying key purchasing entities, regional demand patterns, supplier…